ChemoCentryx Inc (CCXI) Expected to Post Quarterly Sales of $11.37 Million
Analysts forecast that ChemoCentryx Inc (NASDAQ:CCXI) will report $11.37 million in sales for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for ChemoCentryx’s earnings. The highest sales estimate is $15.00 million and the lowest is $9.33 million. ChemoCentryx reported sales of $9.55 million during the same quarter last year, which indicates a positive year over year growth rate of 19.1%. The company is expected to issue its next quarterly earnings results on Wednesday, May 8th.
According to Zacks, analysts expect that ChemoCentryx will report full-year sales of $46.06 million for the current fiscal year, with estimates ranging from $40.00 million to $60.00 million. For the next year, analysts expect that the business will report sales of $49.50 million, with estimates ranging from $40.00 million to $71.83 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow ChemoCentryx.
ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.06. The firm had revenue of $9.33 million during the quarter, compared to analyst estimates of $9.54 million. ChemoCentryx had a negative return on equity of 167.57% and a negative net margin of 88.55%.
In other ChemoCentryx news, Treasurer Markus J. Cappel sold 5,069 shares of the stock in a transaction on Monday, January 7th. The stock was sold at an average price of $12.07, for a total transaction of $61,182.83. Following the completion of the transaction, the treasurer now directly owns 40,510 shares of the company’s stock, valued at $488,955.70. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Susan M. Kanaya sold 37,893 shares of the stock in a transaction on Tuesday, January 22nd. The shares were sold at an average price of $12.08, for a total value of $457,747.44. Following the transaction, the chief financial officer now directly owns 110,746 shares of the company’s stock, valued at $1,337,811.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 78,541 shares of company stock valued at $946,573. 14.50% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Metropolitan Life Insurance Co. NY grew its holdings in ChemoCentryx by 369.8% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,804 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 6,930 shares during the period. Raymond James & Associates bought a new position in ChemoCentryx during the fourth quarter valued at $133,000. SG Americas Securities LLC bought a new position in ChemoCentryx during the fourth quarter valued at $196,000. MetLife Investment Advisors LLC grew its holdings in ChemoCentryx by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 19,233 shares of the biopharmaceutical company’s stock valued at $243,000 after purchasing an additional 6,841 shares during the period. Finally, Man Group plc bought a new position in ChemoCentryx during the third quarter valued at $255,000. 54.11% of the stock is owned by institutional investors and hedge funds.
CCXI traded down $0.03 during midday trading on Monday, reaching $10.19. 313,248 shares of the company were exchanged, compared to its average volume of 323,218. The company has a debt-to-equity ratio of 1.34, a quick ratio of 2.87 and a current ratio of 2.82. The firm has a market capitalization of $516.38 million, a P/E ratio of -13.41 and a beta of 1.28. ChemoCentryx has a one year low of $9.07 and a one year high of $15.08.
ChemoCentryx Company Profile
ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
Recommended Story: Cost of Capital Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.